Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies

Karen W L Yee, Anne Hagey, Srdan Verstovsek, Jorge Cortes, Guillermo Garcia-Manero, Susan M. O'Brien, Stefan Faderl, Deborah Thomas, William Wierda, Steven Kornblau, Alessandra Ferrajoli, Maher Albitar, Evelyn McKeegan, David R. Grimm, Toby Mueller, Rhonda R. Holley-Shanks, Leonardo Sahelijo, Gary B. Gordon, Hagop M. Kantarjian, Francis J. Giles*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Fingerprint Dive into the research topics of 'Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies'. Together they form a unique fingerprint.

Medicine & Life Sciences